Antimicrob Agents Chemother

References in Antimicrob Agents Chemother:

Search this table:

Title	Authors	Year
Comparative inhibition of hepatitis B virus DNA polymerase and cellular DNA polymerases by triphosphates of sugar-modified 5-methyldeoxycytidines and of other nucleoside analogs.	Matthes E, Reimer K, von Janta-Lipinski M, Meisel H, Lehmann C	1991
Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases.	Cherrington JM, Fuller MD, Mulato AS, Allen SJ, Kunder SC, Ussery MA, Lesnikowski Z, Schinazi RF, Sommadossi JP, Chen MS	1996
Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories.	Chou S, Lurain NS, Weinberg A, Cai GY, Sharma PL, Crumpacker CS	1999
(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.	Coates JA, Cammack N, Jenkinson HJ, Jowett AJ, Jowett MI, Pearson BA, Penn CR, Rouse PL, Viner KC, Cameron JM	1992
Response to antiretroviral therapy in a patient with an uncommon codon 69 insertion in the human immunodeficiency virus type 1 reverse transcriptase.	Bonfanti P, Faggion I, La Seta Catamancio S, Violin M, Balotta C, Rusconi S	2000
A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.	Larder BA, Bloor S, Kemp SD, Hertogs K, Desmet RL, Miller V, Sturmer M, Staszewski S, Ren J, Stammers DK, Stuart DI, Pauwels R	1999
3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors.	Larder BA	1992
Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay.	Larder BA, Chesebro B, Richman DD	1990
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.	Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C, Wainberg MA	1993
Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.	Nakata H, Amano M, Koh Y, Kodama EN, Yang G, Bailey CM, Kohgo S, Hayakawa H, Matsuoka M, Anderson KS, Cheng YC, Mitsuya H	2007
Inhibitors of DNA polymerase III as novel antimicrobial agents against gram-positive eubacteria.	Tarantino PM, Zhi C, Wright GE, Brown NC	1999
Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate.	Abele G, Eriksson B, Harmenberg J, Wahren B	1988
Mutually exclusive inhibition of herpesvirus DNA polymerase by aphidicolin, phosphonoformate, and acyclic nucleoside triphosphates.	Frank KB, Cheng YC	1985
Low frequencies of resistance among Staphylococcus and Enterococcus species to the bactericidal DNA polymerase inhibitor N(3)-hydroxybutyl 6-(3'-ethyl-4'-methylanilino) uracil.	Butler MM, Skow DJ, Stephenson RO, Lyden PT, LaMarr WA, Foster KA	2002
Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.	White KL, Chen JM, Margot NA, Wrin T, Petropoulos CJ, Naeger LK, Swaminathan S, Miller MD	2004
ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.	Naeger LK, Margot NA, Miller MD	2002
In vitro antimicrobial activities of novel anilinouracils which selectively inhibit DNA polymerase III of gram-positive bacteria.	Daly JS, Giehl TJ, Brown NC, Zhi C, Wright GE, Ellison RT	2000
Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates.	Meyer PR, Matsuura SE, Schinazi RF, So AG, Scott WA	2000
Azidothymidine triphosphate is an inhibitor of both human immunodeficiency virus type 1 reverse transcriptase and DNA polymerase gamma.	König H, Behr E, Löwer J, Kurth R	1989
Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts.	Hussy P, Maass G, Tümmler B, Grosse F, Schomburg U	1986
4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.	Kodama EI, Kohgo S, Kitano K, Machida H, Gatanaga H, Shigeta S, Matsuoka M, Ohrui H, Mitsuya H	2001
Biological characterization of novel inhibitors of the gram-positive DNA polymerase IIIC enzyme.	Kuhl A, Svenstrup N, Ladel C, Otteneder M, Binas A, Schiffer G, Brands M, Lampe T, Ziegelbauer K, Rübsamen-Waigmann H, Haebich D, Ehlert K	2005
Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.	Hammond JL, Koontz DL, Bazmi HZ, Beadle JR, Hostetler SE, Kini GD, Aldern KA, Richman DD, Hostetler KY, Mellors JW	2001
Inhibition of herpesvirus replication and herpesvirus-induced deoxyribonucleic acid polymerase by phosphonoformate.	Reno JM, Lee LF, Boezi JA	1978
Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition.	Mazzucco CE, Hamatake RK, Colonno RJ, Tenney DJ	2008
The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.	Miranda LR, Götte M, Liang F, Kuritzkes DR	2005
Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214.	Stürmer M, Staszewski S, Doerr HW, Larder BA, Bloor S, Hertogs K	2003
A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives.	Sullivan V, Biron KK, Talarico C, Stanat SC, Davis M, Pozzi LM, Coen DM	1993
Inhibition of cellular alpha DNA polymerase and herpes simplex virus-induced DNA polymerases by the triphosphate of BW759U.	St Clair MH, Miller WH, Miller RL, Lambe CU, Furman PA	1984
The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro.	Coates JA, Cammack N, Jenkinson HJ, Mutton IM, Pearson BA, Storer R, Cameron JM, Penn CR	1992
Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.	White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK	2002
Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.	Marchand B, White KL, Ly JK, Margot NA, Wang R, McDermott MJ, Miller MD, Götte M	2007
Interaction of Epstein-Barr virus DNA polymerase and 5'-triphosphates of several antiviral nucleoside analogs.	Chiou JF, Cheng YC	1985
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.	Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM	2000
Activities of arabinosyladenine monophosphate and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against ground squirrel hepatitis virus in vivo as determined by reduction in serum virion-associated DNA polymerase.	Smee DF, Knight SS, Duke AE, Robinson WS, Matthews TR, Marion PL	1985
Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors.	Byrnes VW, Emini EA, Schleif WA, Condra JH, Schneider CL, Long WJ, Wolfgang JA, Graham DJ, Gotlib L, Schlabach AJ	1994
A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V.	Hertogs K, Bloor S, De Vroey V, van Den Eynde C, Dehertogh P, van Cauwenberge A, Stürmer M, Alcorn T, Wegner S, van Houtte M, Miller V, Larder BA	2000
Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay.	Boucher CA, Keulen W, van Bommel T, Nijhuis M, de Jong D, de Jong MD, Schipper P, Back NK	1996
Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.	Mellors JW, Bazmi HZ, Schinazi RF, Roy BM, Hsiou Y, Arnold E, Weir J, Mayers DL	1995
R964C mutation of DNA polymerase gamma imparts increased stavudine toxicity by decreasing nucleoside analog discrimination and impairing polymerase activity.	Bailey CM, Kasiviswanathan R, Copeland WC, Anderson KS	2009
Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells.	Robbins BL, Greenhaw J, Connelly MC, Fridland A	1995
Mutation within the herpes simplex virus DNA polymerase gene conferring resistance to (R)-9-(3,4-dihydroxybutyl)guanine.	Chiou HC, Kerns KM, Coen DM	1986
TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.	Andries K, Azijn H, Thielemans T, Ludovici DW, Kukla M, Heeres J, Janssen PA, De Corte B, Vingerhoets J, Pauwels R, De Béthune MP	2004
Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase.	Tenney DJ, Yamanaka G, Voss SM, Cianci CW, Tuomari AV, Sheaffer AK, Alam M, Colonno RJ	1997
Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation.	Xiong X, Smith JL, Chen MS	1997
Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase.	Meyer PR, Matsuura SE, Tolun AA, Pfeifer I, So AG, Mellors JW, Scott WA	2002
Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand.	Magee WC, Aldern KA, Hostetler KY, Evans DH	2008
Lersivirine: a Non-Nucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus-1.	Corbau R, Mori J, Phillips C, Fishburn L, Martin A, Mowbray C, Panton W, Smith-Burchnell C, Thornberry A, Ringrose H, Knöchel T, Irving S, Westby M, Wood A, Perros M	2010
Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate.	Magee WC, Hostetler KY, Evans DH	2005
Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase.	Frankel FA, Marchand B, Turner D, Götte M, Wainberg MA	2005
Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones.	Didierjean J, Isel C, Querré F, Mouscadet JF, Aubertin AM, Valnot JY, Piettre SR, Marquet R	2005
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.	Schinazi RF, Lloyd RM, Nguyen MH, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ, Mellors JW	1993

Showing 1 to 52 of 52 entries